Tranzyme Pharma receives notice of allowance from USPTO for its patent application (PharmaBiz)
Tranzyme Pharma receives notice of allowance from USPTO for its patent application (PharmaBiz)
Tranzyme Pharma, a leading biopharmaceutical company developing novel mechanism-based therapeutics for the treatment of gastrointestinal (GI) and metabolic disorders, has received a Notice of Allowance from the US Patent and Trademark Office (USPTO) for its patent application entitled “Combinatorial Synthesis of Libraries of Macrocyclic Compounds.”